Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib

NCT00733408 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT00733408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00733408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Completed
Start date
April 23, 2008
Completion date
September 28, 2017
Enrollment
59 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor-negative breast cancer, her2-negative breast cancer, progesterone receptor-negative breast cancer, recurrent breast cancer, stage iv breast cancer, triple-negative breast cancer